LuciLaro (Larotrectinib) 100mg×30 Capsules | Lucius Laos NTRK Fusion | GLT

Generic Information: LuciLaro (Larotrectinib) — Lucius Pharmaceuticals, Laos

LuciLaro is the larotrectinib capsule of Lucius Pharmaceuticals (Lao) Co., Ltd., the Vientiane-based manufacturer whose precision oncology portfolio spans several fusion-driven targets. The presentation is 100 mg capsules in a 30-capsule bottle, registered with the Lao Food and Drug Department under number 05L 0977/23. Lucius positions it as a direct generic of Vitrakvi for the standard adult dose of 100 mg twice daily, with the single-strength bottle keeping supply and inventory straightforward for buyers sourcing from Laos.

What Is LuciLaro (Larotrectinib) Used For?

LuciLaro treats adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, where disease is metastatic or surgery would likely cause severe morbidity, and where there is no satisfactory alternative or the cancer has progressed after treatment. The indication is defined by the fusion, not the organ, so it applies to infantile fibrosarcoma, salivary gland cancer, soft-tissue sarcoma, thyroid cancer, lung cancer and other NTRK fusion-positive solid tumors once a validated test confirms the fusion.

How Does LuciLaro (Larotrectinib) Work?

The active ingredient selectively inhibits the tropomyosin receptor kinase (TRK) family — TRKA, TRKB and TRKC, encoded by the NTRK1, NTRK2 and NTRK3 genes. An NTRK fusion produces an always-on TRK fusion protein that drives tumor growth regardless of location; by blocking all three TRK kinases, larotrectinib cuts that signal and shrinks tumors across tissues. The capsule is the sulfate salt formulation, taken orally twice daily, matching the originator's pharmacology.

Indications of LuciLaro (Lao Label)

The Lao label mirrors the originator's tissue-agnostic indication: NTRK fusion-positive solid tumors without acquired resistance, locally advanced or metastatic or high-risk-for-surgery, and no satisfactory alternative or progression after prior therapy. The critical rule is patient selection — a validated test must confirm the fusion, because the drug has minimal activity in fusion-negative tumors and in those with acquired TRK resistance mutations such as G595R.

Dosage and Administration

The recommended dose is 100 mg orally twice daily for adults and children with body surface area of at least 1.0 m², with or without food, until progression or unacceptable toxicity; children below 1.0 m² receive 100 mg/m² twice daily. Capsules are swallowed whole, never chewed or crushed, and a missed dose is skipped if within six hours of the next scheduled dose. Toxicity reductions step through 75 mg and 50 mg twice daily to 100 mg once daily, and strong CYP3A4 inhibitors or inducers require dose adjustment.

Side Effects of LuciLaro

The common reactions, in at least 20% of patients, are fatigue, nausea, dizziness, vomiting, cough, constipation, diarrhea and raised AST and ALT. Neurotoxicity — dizziness, cognitive impairment, mood and sleep disturbance — warrants caution with driving and machinery, and hepatotoxicity is managed with liver-function monitoring every two weeks early on and monthly thereafter. Skeletal fractures warrant prompt evaluation, and effective contraception is required during and for one week after treatment because of fetal risk.

Storage Instructions

Store the 30-capsule bottle at 20°C to 25°C, with excursions of 15°C to 30°C permitted, in a closed container protected from moisture and out of children's reach. Lucius stock is sealed with the Lao registration number 05L 0977/23 and a batch number, giving buyers a verifiable provenance for a generic sourced from Laos.

Why Choose LuciLaro from GLT?

LuciLaro is the Laos option for buyers who want a Lucius-manufactured generic of this tissue-agnostic TRK inhibitor at a competitive price. GLT quotes it beside the originator Vitrakvi and the Bangladesh generics (Laronib, Tractoni) plus the other Laos options (Larotreni, Larodx), so the full NTRK landscape is visible before a decision. Sealed stock with pre-shipment photographs and export documentation comes standard, and a real person answers on WhatsApp +86 15234153837 or at [email protected].

How to Order LuciLaro (Larotrectinib)

Message GLT on WhatsApp +86 15234153837 or write to [email protected] with the bottle quantity and destination. A formal quotation with courier and payment options returns within a working day, and recurring supply can be scheduled for continuous twice-daily therapy. Confirmed orders ship sealed with complete export paperwork.

FAQ

Is LuciLaro the same as Vitrakvi? Same active ingredient and dose; LuciLaro is the Lucius Laos generic.

What is the Lao registration number? 05L 0977/23, issued by the Lao Food and Drug Department.

Does it need a gene test? Yes — NTRK fusion must be confirmed by a validated test before treatment.

Is it chemotherapy? No, it is an oral targeted TRK inhibitor.

Can children take it? Yes, with body-surface-area-based dosing.